Semaglutide Overview

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It has gained massive attention for metabolic research after FDA approval of branded versions (Ozempic, Wegovy). Research focuses on glucose metabolism, appetite regulation, and body composition. It has one of the longest half-lives among GLP-1 agonists at approximately 7 days.

CJC-1295 Overview

CJC-1295 is a synthetic GHRH analog that stimulates growth hormone release from the pituitary gland. The DAC version extends its half-life to approximately 8 days through albumin binding. Research focuses on GH axis stimulation, body composition, recovery, and age-related GH decline.

Head-to-Head Comparison

Feature	Semaglutide	CJC-1295
Class	GLP-1 receptor agonist	GHRH analog
Target Hormone	GLP-1/Insulin axis	Growth hormone axis
Primary Research	Metabolic, weight	GH stimulation, recovery
Half-Life	~7 days	~8 days (DAC)
FDA Status	Approved (branded)	Not approved
Price (5mg)	$50-90	$35-55

Key Differences

These peptides operate on completely different hormonal systems. Semaglutide targets the GLP-1/incretin system, affecting insulin secretion, appetite, and glucose metabolism. CJC-1295 targets the growth hormone axis, stimulating GH and IGF-1 production. Semaglutide has extensive FDA-approved clinical data through its branded versions, while CJC-1295 remains primarily a research compound. Both have long half-lives (~7-8 days) allowing infrequent dosing in research protocols.

Which Should You Choose?

Choose Semaglutide for metabolic research, glucose metabolism, appetite regulation, and weight-related studies. Choose CJC-1295 for growth hormone research, recovery studies, and age-related GH decline. These peptides are not typically interchangeable as they target fundamentally different systems. Some researchers study body composition effects of both, though through different mechanisms.

Frequently Asked Questions

Can Semaglutide and CJC-1295 be combined?

While they target different systems, some body composition research protocols study both — Semaglutide for metabolic/appetite effects and CJC-1295 for GH-mediated anabolic effects. However, combined protocols require careful design.

Which is better for body composition research?

Both affect body composition but through different mechanisms. Semaglutide primarily reduces appetite and fat mass, while CJC-1295 promotes lean mass through GH stimulation. The choice depends on the specific research question.